Swiss Prime Site successfully placed green bonds in the aggregate principal amount of CHF 250 million 1.80% due 2030. The bonds were issued by Swiss Prime Site Finance AG and guaranteed by Swiss Prime Site AG. Zürcher Kantonalbank, Basellandschaftliche Kantonalbank and Luzerner Kantonalbank AG acted as Joint Lead Managers in this transaction.

On 8 March 2024, Roche Holdings, Inc. successfully completed its issuance of USD 3.875 billion in aggregate principal amount of senior notes, consisting of USD 875 million 4.790% Notes due 2029, USD 750 million 4.909% Notes due 2031, USD 1.25 billion 4.985% Notes due 2034, and USD 1 billion 5.218% Notes due 2054. The notes are irrevocably and unconditionally guaranteed by Roche Holding Ltd.

On 12 March 2024, Nestlé Capital Corporation successfully completed its issuance of USD 600 million 4.650% Notes due 2029, USD 450 million 4.750% Notes due 2031, USD 800 million 4.875% Notes due 2034, and USD 650 million 5.100% Notes due 2054. The Notes are guaranteed by the Nestlé group’s Swiss parent company Nestlé S.A. The offering of the Notes was done in reliance on Rule 144A and Regulation S under the U.S. Securities Act.

On 22 March 2024, the shares of Galderma Group AG, a pure-play dermatology category leader, were listed and started trading on SIX Swiss Exchange at a price of CHF 53 per share. Based on the offer price, Galderma’s implied market capitalization was CHF 12.6 billion. During the IPO, the syndicate banks successfully placed 37,233,708 newly issued registered shares, as well as 276,909 existing registered shares offered by one of Galderma’s shareholders, Sunshine SwissCo AG (EQT). EQT, together with certain of Galderma Group AG’s other shareholders, granted a secondary over-allotment option of up to 5,626,592 existing registered shares, which was exercised in full. The total placement volume was CHF 2.3 billion. On 25 March 2024, Galderma was granted inclusion to SPI, SPI Extra, SPI ex Swiss Leader Index, SXI Life Sciences, UBS 100 and Ethos Swiss Corporate Governance. Galderma raised gross proceeds of CHF 2.0 billion from the offering, and intends to use the proceeds primarily to strengthen its balance sheet by repaying and refinancing debt. 

At its AGM held on 26 March 2024, SGS SA proposed to shareholders, and an overwhelming majority approved, the right to receive a dividend in the form of either cash or shares of the company (scrip dividend) at the option of eligible shareholders. The shares to be delivered will be valued at a discount of 6% to the market value of the SGS shares, offering attractive tax benefits for shareholders (no withholding tax and no income tax for certain shareholders). The new shares will be sourced by way of an ordinary capital increase also approved by the shareholders at the AGM.

On 2 April 2024, Meyer Burger Technology AG announced that as part of its rights offering, subscription rights for 19,648,121,444 new shares were exercised. On 3 April 2024, Meyer Burger announced that all 496,302,442 new shares for which subscription rights were not exercised during the subscription period were successfully placed with various institutional investors. As a result, Meyer Burger issued 20,144,423,886 new registered shares in connection with the capital increase and raised gross proceeds of CHF 206.75 million. 

Clariant AG successfully placed a CHF 200 million bond with a term to maturity of three years, and a CHF 150 million bond with a term to maturity of seven years. The net proceeds will be used for general corporate purposes. 

On 4 April 2024, Medartis Holding AG announced the successful placement of senior unsecured guaranteed convertible bonds due 2031 for an amount of CHF 115.8 million, convertible into newly issued and/or existing registered shares of Medartis Holding AG. The bonds are issued via Medartis International Finance SAS, a directly wholly owned subsidiary of Medartis Holding AG, and the payment obligations under the bonds are unconditionally and irrevocably guaranteed by Medartis Holding AG. An application will be made for the bonds to be admitted to trading on the Open Market of the Frankfurt Stock Exchange (Freiverkehr). The net proceeds from the bonds issue will be used for general funding purposes including acquisitions in Medartis’ core business. 

On 18 April 2024, Swiss Steel Holding AG announced the placement of a total of 3,101,000,000 new registered shares in connection with its capital increase. The shares were sold at an offer price of CHF 0.0925 per share, resulting in gross proceeds of EUR 300 million and net proceeds of approximately EUR 294 million. The transaction was fully backstopped by BigPoint Holding AG.

On 18 April 2024, DocMorris announced the successful placement of senior unsecured guaranteed convertible bonds due 2029 for an amount of CHF 200 million, convertible into newly issued and/or existing registered shares of DocMorris AG. The bonds are issued via DocMorris Finance B.V., a directly wholly owned subsidiary of DocMorris AG, and the payment obligations under the bonds are unconditionally and irrevocably guaranteed by DocMorris AG. With the transaction, DocMorris intends to refinance the outstanding CHF122m convertible bonds due 2025. For this purpose, DocMorris announced a public repurchase offer for outstanding convertible bonds due 2025 at an offer price of CHF 5,037.50 per bond corresponding to 100.75% of the par value, plus accrued and unpaid interest.